Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

How does aging impact decision making? The contribution of cognitive decline and strategic compensation revealed in a cognitive architecture.

Fechner HB, Pachur T, Schooler LJ.

J Exp Psychol Learn Mem Cogn. 2019 Sep;45(9):1634-1663. doi: 10.1037/xlm0000661. Epub 2019 Mar 4.

PMID:
30829515
2.

Generation of a 3D Liver Model Comprising Human Extracellular Matrix in an Alginate/Gelatin-Based Bioink by Extrusion Bioprinting for Infection and Transduction Studies.

Hiller T, Berg J, Elomaa L, Röhrs V, Ullah I, Schaar K, Dietrich AC, Al-Zeer MA, Kurtz A, Hocke AC, Hippenstiel S, Fechner H, Weinhart M, Kurreck J.

Int J Mol Sci. 2018 Oct 12;19(10). pii: E3129. doi: 10.3390/ijms19103129.

3.

Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis.

Pappritz K, Savvatis K, Miteva K, Kerim B, Dong F, Fechner H, Müller I, Brandt C, Lopez B, González A, Ravassa S, Klingel K, Diez J, Reinke P, Volk HD, Van Linthout S, Tschöpe C.

FASEB J. 2018 Jun 4:fj201701408R. doi: 10.1096/fj.201701408R. [Epub ahead of print]

PMID:
29863913
4.

Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.

Hazini A, Pryshliak M, Brückner V, Klingel K, Sauter M, Pinkert S, Kurreck J, Fechner H.

Hum Gene Ther. 2018 Nov;29(11):1301-1314. doi: 10.1089/hum.2018.036. Epub 2018 Jun 20.

PMID:
29739251
5.

RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors.

Valdor M, Wagner A, Röhrs V, Berg J, Fechner H, Schröder W, Tzschentke TM, Bahrenberg G, Christoph T, Kurreck J.

Mol Pain. 2018 Jan-Dec;14:1744806917749669. doi: 10.1177/1744806917749669. Epub 2017 Dec 6.

6.

The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis.

Loebel M, Holzhauser L, Hartwig JA, Shukla PC, Savvatis K, Jenke A, Gast M, Escher F, Becker SC, Bauer S, Stroux A, Beling A, Kespohl M, Pinkert S, Fechner H, Kuehl U, Lassner D, Poller W, Schultheiss HP, Zeller T, Blankenberg S, Papageorgiou AP, Heymans S, Landmesser U, Scheibenbogen C, Skurk C.

Eur Heart J. 2018 Mar 7;39(10):876-887. doi: 10.1093/eurheartj/ehx624.

PMID:
29136142
7.

Infection of iPSC Lines with Miscarriage-Associated Coxsackievirus and Measles Virus and Teratogenic Rubella Virus as a Model for Viral Impairment of Early Human Embryogenesis.

Hübner D, Jahn K, Pinkert S, Böhnke J, Jung M, Fechner H, Rujescu D, Liebert UG, Claus C.

ACS Infect Dis. 2017 Dec 8;3(12):886-897. doi: 10.1021/acsinfecdis.7b00103. Epub 2017 Oct 26.

PMID:
29043768
8.

Cognitive costs of decision-making strategies: A resource demand decomposition analysis with a cognitive architecture.

Fechner HB, Schooler LJ, Pachur T.

Cognition. 2018 Jan;170:102-122. doi: 10.1016/j.cognition.2017.09.003. Epub 2017 Oct 5.

PMID:
28987923
9.

Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters.

Schaar K, Geisler A, Kraus M, Pinkert S, Pryshliak M, Spencer JF, Tollefson AE, Ying B, Kurreck J, Wold WS, Klopfleisch R, Toth K, Fechner H.

Mol Ther Nucleic Acids. 2017 Sep 15;8:300-316. doi: 10.1016/j.omtn.2017.07.002. Epub 2017 Jul 8.

10.

NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.

Tschöpe C, Müller I, Xia Y, Savvatis K, Pappritz K, Pinkert S, Lassner D, Heimesaat MM, Spillmann F, Miteva K, Bereswill S, Schultheiss HP, Fechner H, Pieske B, Kühl U, Van Linthout S.

Circ Heart Fail. 2017 Sep;10(9). pii: e003870. doi: 10.1161/CIRCHEARTFAILURE.117.003870.

PMID:
28912259
11.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
12.

Influence of Posture-Cuing Shirt on Tennis Serve Kinematics in Division III Tennis Players.

Zappala J, Orrego C, Boe E, Fechner H, Salminen D, Cipriani DJ.

J Chiropr Med. 2017 Mar;16(1):49-53. doi: 10.1016/j.jcm.2016.05.003. Epub 2016 Nov 18.

13.

Silencing Genes in the Heart.

Fechner H, Vetter R, Kurreck J, Poller W.

Methods Mol Biol. 2017;1521:17-39.

PMID:
27910039
14.

Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2.

Hiller T, Röhrs V, Dehne EM, Wagner A, Fechner H, Lauster R, Kurreck J.

J Vis Exp. 2016 Oct 24;(116). doi: 10.3791/54633.

15.

Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.

Pinkert S, Dieringer B, Diedrich S, Zeichhardt H, Kurreck J, Fechner H.

Antiviral Res. 2016 Dec;136:1-8. doi: 10.1016/j.antiviral.2016.10.010. Epub 2016 Oct 20.

PMID:
27773751
16.

Strategies for memory-based decision making: Modeling behavioral and neural signatures within a cognitive architecture.

Fechner HB, Pachur T, Schooler LJ, Mehlhorn K, Battal C, Volz KG, Borst JP.

Cognition. 2016 Dec;157:77-99. doi: 10.1016/j.cognition.2016.08.011. Epub 2016 Sep 3.

PMID:
27597646
17.

MicroRNA-regulated viral vectors for gene therapy.

Geisler A, Fechner H.

World J Exp Med. 2016 May 20;6(2):37-54. doi: 10.5493/wjem.v6.i2.37. eCollection 2016 May 20. Review.

18.

Biological antivirals for treatment of adenovirus infections.

Schaar K, Röger C, Pozzuto T, Kurreck J, Pinkert S, Fechner H.

Antivir Ther. 2016;21(7):559-566. doi: 10.3851/IMP3047. Epub 2016 Apr 1. Review.

PMID:
27032991
19.

The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.

Pinkert S, Röger C, Kurreck J, Bergelson JM, Fechner H.

J Virol. 2016 May 27;90(12):5601-5610. doi: 10.1128/JVI.00315-16. Print 2016 Jun 15.

20.

Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.

Wagner A, Bock CT, Fechner H, Kurreck J.

Future Med Chem. 2015;7(13):1637-42. doi: 10.4155/fmc.15.114. Epub 2015 Sep 18. No abstract available.

PMID:
26381598
21.

Use of a three-dimensional humanized liver model for the study of viral gene vectors.

Wagner A, Röhrs V, Materne EM, Hiller T, Kedzierski R, Fechner H, Lauster R, Kurreck J.

J Biotechnol. 2015 Oct 20;212:134-43. doi: 10.1016/j.jbiotec.2015.08.012. Epub 2015 Sep 7.

PMID:
26356676
22.

[Newborn Hearing Screening - Results of a Parental Survey in Saxony-Anhalt].

Müller J, Fechner H, Köhn A, Rißmann A.

Gesundheitswesen. 2017 May;79(5):388-393. doi: 10.1055/s-0035-1549969. Epub 2015 Jun 25. German.

PMID:
26110244
23.

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.

Pozzuto T, Röger C, Kurreck J, Fechner H.

Antiviral Res. 2015 Aug;120:72-8. doi: 10.1016/j.antiviral.2015.05.010. Epub 2015 May 27.

PMID:
26026665
24.

Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy.

Schmidt-Lucke C, Zobel T, Schrepfer S, Kuhl U, Wang D, Klingel K, Becher PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Escher F, Holinski S, Volk HD, Schultheiss HP, Tschope C.

J Infect Dis. 2015 Oct 1;212(7):1070-81. doi: 10.1093/infdis/jiv178. Epub 2015 Mar 24.

PMID:
25805750
25.

Expression of an engineered soluble coxsackievirus and adenovirus receptor by a dimeric AAV9 vector inhibits adenovirus infection in mice.

Röger C, Pozzuto T, Klopfleisch R, Kurreck J, Pinkert S, Fechner H.

Gene Ther. 2015 Jun;22(6):458-66. doi: 10.1038/gt.2015.19. Epub 2015 Mar 19.

PMID:
25786873
26.

Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.

Stein EA, Pinkert S, Becher PM, Geisler A, Zeichhardt H, Klopfleisch R, Poller W, Tschöpe C, Lassner D, Fechner H, Kurreck J.

J Infect Dis. 2015 Feb 15;211(4):613-22. doi: 10.1093/infdis/jiu504. Epub 2014 Sep 5.

PMID:
25193982
27.

Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

von Kietzell K, Pozzuto T, Heilbronn R, Grössl T, Fechner H, Weger S.

J Virol. 2014 Jul;88(14):8102-15. doi: 10.1128/JVI.00649-14. Epub 2014 May 7.

28.

Interspecies differences in virus uptake versus cardiac function of the coxsackievirus and adenovirus receptor.

Freiberg F, Sauter M, Pinkert S, Govindarajan T, Kaldrack J, Thakkar M, Fechner H, Klingel K, Gotthardt M.

J Virol. 2014 Jul;88(13):7345-56. doi: 10.1128/JVI.00104-14. Epub 2014 Apr 16.

29.

A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.

Gröβl T, Hammer E, Bien-Möller S, Geisler A, Pinkert S, Röger C, Poller W, Kurreck J, Völker U, Vetter R, Fechner H.

PLoS One. 2014 Mar 26;9(3):e92188. doi: 10.1371/journal.pone.0092188. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107093.

30.

A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard.

Wagner A, Röhrs V, Kedzierski R, Fechner H, Kurreck J.

Hum Gene Ther Methods. 2013 Dec;24(6):355-63. doi: 10.1089/hgtb.2013.095. Epub 2013 Oct 16.

PMID:
23987130
31.

Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication.

Brandt MR, Kirste AG, Pozzuto T, Schubert S, Kandolf R, Fechner H, Bock CT, Kurreck J.

Virus Res. 2013 Sep;176(1-2):155-60. doi: 10.1016/j.virusres.2013.05.020. Epub 2013 Jun 13.

PMID:
23770153
32.

Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors.

Geisler A, Schön C, Größl T, Pinkert S, Stein EA, Kurreck J, Vetter R, Fechner H.

Mol Ther. 2013 May;21(5):924-33. doi: 10.1038/mt.2012.276. Epub 2013 Feb 26.

33.

Roles of E4orf6 and VA I RNA in adenovirus-mediated stimulation of human parvovirus B19 DNA replication and structural gene expression.

Winter K, von Kietzell K, Heilbronn R, Pozzuto T, Fechner H, Weger S.

J Virol. 2012 May;86(9):5099-109. doi: 10.1128/JVI.06991-11. Epub 2012 Feb 22.

34.

Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-α-induced apoptosis.

Boltzen U, Eisenreich A, Antoniak S, Weithaeuser A, Fechner H, Poller W, Schultheiss HP, Mackman N, Rauch U.

J Mol Cell Cardiol. 2012 May;52(5):1056-65. doi: 10.1016/j.yjmcc.2012.01.015. Epub 2012 Jan 31.

35.

Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.

Fechner H, Pinkert S, Geisler A, Poller W, Kurreck J.

Molecules. 2011 Oct 11;16(10):8475-503. doi: 10.3390/molecules16108475. Review.

36.

Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Pinkert S, Klingel K, Lindig V, Dörner A, Zeichhardt H, Spiller OB, Fechner H.

J Virol. 2011 Dec;85(24):13409-19. doi: 10.1128/JVI.00621-11. Epub 2011 Oct 5.

37.

Involvement of p32 and microtubules in alteration of mitochondrial functions by rubella virus.

Claus C, Chey S, Heinrich S, Reins M, Richardt B, Pinkert S, Fechner H, Gaunitz F, Schäfer I, Seibel P, Liebert UG.

J Virol. 2011 Apr;85(8):3881-92. doi: 10.1128/JVI.02492-10. Epub 2011 Jan 19.

38.

Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions.

Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H.

Virology. 2011 Mar 1;411(1):50-64. doi: 10.1016/j.virol.2010.12.019. Epub 2011 Jan 13.

39.

Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats.

Vetter R, Rehfeld U, Reissfelder C, Fechner H, Seppet E, Kreutz R.

Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H943-50. doi: 10.1152/ajpheart.00490.2010. Epub 2011 Jan 7.

40.

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S.

Vaccine. 2011 Feb 11;29(8):1690-9. doi: 10.1016/j.vaccine.2010.12.037. Epub 2010 Dec 30.

PMID:
21195079
41.

Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator.

Rother M, Krohn S, Kania G, Vanhoutte D, Eisenreich A, Wang X, Westermann D, Savvatis K, Dannemann N, Skurk C, Hilfiker-Kleiner D, Cathomen T, Fechner H, Rauch U, Schultheiss HP, Heymans S, Eriksson U, Scheibenbogen C, Poller W.

Circulation. 2010 Dec 21;122(25):2688-98. doi: 10.1161/CIRCULATIONAHA.110.945261. Epub 2010 Dec 6.

42.

microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors.

Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, Fechner H, Müller OJ.

Gene Ther. 2011 Feb;18(2):199-209. doi: 10.1038/gt.2010.141. Epub 2010 Nov 4.

PMID:
21048795
43.

Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.

Fecker LF, Rückert S, Kurbanov BM, Schmude M, Stockfleth E, Fechner H, Eberle J.

Hum Gene Ther. 2011 Apr;22(4):405-17. doi: 10.1089/hum.2010.108. Epub 2011 Feb 16.

PMID:
20977303
44.

Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions.

Eckstein A, Grössl T, Geisler A, Wang X, Pinkert S, Pozzuto T, Schwer C, Kurreck J, Weger S, Vetter R, Poller W, Fechner H.

Antiviral Res. 2010 Oct;88(1):86-94. doi: 10.1016/j.antiviral.2010.08.002. Epub 2010 Aug 11.

PMID:
20708037
45.

Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30.

Rothe D, Wajant G, Grunert HP, Zeichhardt H, Fechner H, Kurreck J.

Oligonucleotides. 2010 Aug;20(4):191-8. doi: 10.1089/oli.2010.0236.

PMID:
20649454
46.
47.

Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Poller W, Hajjar R, Schultheiss HP, Fechner H.

Cardiovasc Res. 2010 Jun 1;86(3):353-64. doi: 10.1093/cvr/cvq056. Epub 2010 Feb 22. Review.

48.

Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.

Pinkert S, Westermann D, Wang X, Klingel K, Dörner A, Savvatis K, Grössl T, Krohn S, Tschöpe C, Zeichhardt H, Kotsch K, Weitmann K, Hoffmann W, Schultheiss HP, Spiller OB, Poller W, Fechner H.

Circulation. 2009 Dec 8;120(23):2358-66. doi: 10.1161/CIRCULATIONAHA.108.845339. Epub 2009 Nov 23.

PMID:
19933937
49.

Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

Bhonde MR, Hanski ML, Stehr J, Jebautzke B, Peiró-Jordán R, Fechner H, Yokoyama KK, Lin WC, Zeitz M, Hanski C.

Int J Cancer. 2010 Jun 15;126(12):2813-25. doi: 10.1002/ijc.24893.

50.

Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus.

Fecker LF, Schmude M, Jost S, Hossini AM, Picó AH, Wang X, Schwarz C, Fechner H, Eberle J.

Exp Dermatol. 2010 Aug;19(8):e56-66. doi: 10.1111/j.1600-0625.2009.00977.x.

Supplemental Content

Loading ...
Support Center